Pfizer Lyme Vaccine Results: 70% Efficacy, Regulatory Review Ahead

Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate with 70% efficacy, but the trial did not meet its primary endpoint due to lower than expected Lyme disease incidence. Despite this, the companies plan to move ahead with regulatory submissions. The vaccine update adds a fresh piece to Pfizer's story beyond its established franchises, and investors may track how it fits into Pfizer's broader vaccine offerings and what it could mean for the company's revenue mix if approved.